|Day Low/High||1.08 / 1.15|
|52 Wk Low/High||0.23 / 2.31|
The market has strengthened a bit since our last update. T2 Biosystems is now up over 50% on positive developments that we chronicled in my last post. Lexicon Pharmaceuticals is up some 30% today off oversold levels. It should receive some $260 mil...
It's a decent start to the trading day as all the major indices are slightly in the green. We are seeing a lot of small biotech stocks I have profiled in these pages rallying on news. Let's start with T2 Biosystems . It is up 25% today as it was awa...
Striking out is painful, but is not as impactful as missing out on the next potential home run because you're still brooding about whiffing on your last investment.
The stocks of these two developmental concerns have slid recently, but there are reasons to believe they will improve.
Small-caps have done better than their bigger brethren so far in 2019, and these three stocks are a reason why.
Exelixis Inc. and Aratana Therapeutics in particular surge after posting solid results Thursday.
This is why I always have some 'dry powder' to deploy during these temporary hiccups.
Diagnostic firms can have an advantage of recurring revenue streams.
BioDelivery Sciences, Neos Therapeutics and Invitae Corp. are delivering big increases in sales.
Patient investors can profit from small-cap biotech stocks that often slide once positive news comes out.
Verastem Inc., T2 Biosystems Inc. and Resonant Inc. have great long-term growth prospects.
T2 Biosystems' recent run-up on a positive event provides an important lesson for biotech investors.
They may not get all the attention, but antibiotic drugs are increasingly important.
T2 Biosystems used the run-up on a positive event - an FDA approval - to raise additional capital.
Markets off to a decent start to the trading day with all the major indices up a half hour into trading. Some of the names I have profiled in recent months are on the move early today. Let's take a look at a few of these: T2 Biosystems after posting...
From ANI Pharmaceuticals to T2 Biosystems, these names look good.
The major indices have improved a tad since our last update. Biotech has shown some strength over the past two hours or so. There are two names to keep an eye on: T2 Biosystems has been strong so far in 2018, moving from around $4 to over $5 a shar...
After Roche's acquisition of Ignyta, I have high hopes for these other two names in 2018.
The Nasdaq Biotech Index is up 25% so far this year
T2 Biosystems and Synergy Pharmaceuticals offer promising prospects at reasonable prices.